Airway Smooth Muscle and Asthma Severity

Asthma Clinical Trial

Official title:

Evaluating the Role of Oxidant/Anti-oxidant Balance and the Relationship of Asthma Severity on Airway Smooth Muscle Proliferation, Migration and Cytokine Release.

Clinical Trial Details — Status: Completed

Administrative data

• NCT number: NCT00779870
• Other study ID #: 08/H0708/2
• Status: Completed
• Start date: October 2008
• Est. completion date: September 2012

Study information

• Verified date: October 2019
• Source: Imperial College London
• Contact: n/a
• Is FDA regulated: No
• Study type: Observational

Clinical Trial Summary

Our hypothesis is that the severity of asthma is determined by the way in which airway smooth muscle cells grow and release inflammatory mediators. Our main objective is to establish how the properties of the airway smooth muscle cell varies with asthma severity. Environmental agents, such as cigarette smoke, and inflammation can give rise to oxidative stress - this is a process whereby harmful chemicals called free radicals are formed in the body and damage tissues. The damage caused can be limited/prevented by protective, or anti-oxidant mediators. We will also look at molecules involved in oxidative stress which may affect the way in which the airway smooth muscle grows and produces inflammatory mediators.

Description:

Aims and Objectives The objective of this study is to examine whether the severity of asthma is related to (and possibly caused by) ASM dysfunction. Severe asthmatics have been shown to have more ASM in bronchial biopsies than non-severe asthmatics16. Because ASM cells can be obtained from bronchial biopsies obtained via bronchoscopy, we will examine endobronchial biopsies from mild, moderate and severe asthmatics, and healthy non-asthmatic subjects to compare features of remodelling (severe asthmatic subjects will have been assessed through the Difficult Asthma Protocol at the Royal Brompton Hospital24). In particular, we will focus on ASM mass, proliferation and changes in expression of different contractile proteins (α-actin and myosin) and chemokines, and will assess in vitro the response of ASM cells to stimulation by TGF-β and IL-1β. We will also examine the effect of dexamethasone on chemokine release and induced proliferation in vitro. We will also study enzymes and anti-oxidants involved in oxidative stress, such as Nox4, MnSOD and catalase, to look at their role in regulating ASM cell proliferation and chemokine synthesis. We want to see if there is an oxidant-anti oxidant balance in ASM in severe asthma compared to non-severe asthma.

AIM:

1. To establish the difference in ASM phenotype in asthma patients of differing severity of disease in terms of ASM mass, proliferation, migration and chemokine release.

Study design There will be 3 study visits. In the first two visits, the subjects will undergo spirometry with reversibility testing, a methacholine challenge test (to assess degree of bronchial hyper-responsiveness), skin prick tests and IgE levels (to assess atopic status), measurement of exhaled nitric oxide (as a non-invasive marker of inflammation), and the asthmatic subjects will complete an Asthma Control Questionnaire and an Asthma Quality of Life Questionnaire. The third visit will be on the day admission for the bronchoscopy.

Study protocol:

Visit 1 - screening visit

• Explain purpose of study- address any queries/concerns

• History and examination

• Skin prick tests

• Blood test for full blood count, clotting profile and IgE

• Measurement of exhaled nitric oxide (eNO)

• Spirometry pre and post β agonist

• Completion of Asthma Control Questionnaire and

• Completion of Asthma Quality of Life Questionnaire

Visit 2 - Methacholine challenge test

Visit 3 - Day admission for fibreoptic bronchoscopy

Recruitment information / eligibility

• Status: Completed
• Enrollment: 18
• Est. completion date: September 2012
• Est. primary completion date: September 2012
• Accepts healthy volunteers: Accepts Healthy Volunteers
• Gender: All
• Age group: 18 Years to 60 Years

Eligibility

Inclusion criteria - Asthma Age 18-60 Physician diagnosis of asthma Intermittent/mild, moderate and severe asthma as per GINA guidelines [1]

For the severe asthma subjects, they will also have the following:

Major characteristics (at least one of the following criteria)

• Treatment with continuous or near continuous (>50% of year) oral corticosteroids

• Requirement for treatment with high dose inhaled corticosteroids (ICS) Minor characteristics (at least 2 out of the following)

1. Requirement for daily treatment with a controller medication in addition to ICS e.g. LABA, theophylline, leukotriene antagonist

2. Asthma symptoms requiring SABA on a daily or near daily basis

3. Persistent airways obstruction (FEV1 <80% predicted, diurnal PEF variation >20%)

4. One or more emergency care visits for asthma per year

5. 3 or more steroid "bursts" per year

6. Prompt deterioration with = 25% reduction in oral or ICS

7. Near fatal asthma event in the past

Reference [1] GINA - The Global Initiative for Asthma. www.ginasthma.com

Exclusion criteria - Asthma Intubation for asthma within 6 months of entry into this study Current smokers, or less than 3 years since quitting smoking (< 5 pack/years) Less than 4 weeks from an exacerbation On steroid-sparing agent or immunosuppressant such as azathioprine, methotrexate and ciclosporin Concomitant anti-IgE therapy On anti-platelet or anti-coagulant drugs Low platelet count Pregnancy or breast-feeding Previous bronchoscopy within three months of this study

Healthy volunteer subjects:

We are aiming for 5 atopic and 5 non-atopic healthy volunteers.

Inclusion criteria:

Age 18 - 60 Non smokers (or less than 5 pack/yrs if ex-smokers) Normal lung function

Exclusion criteria:

History of asthma or allergic rhinitis Any chronic illness Current smokers, or less than 3 years since quitting smoking (< 5 pack/years) PC20 less than 16mg/ml On anti-platelet or anti-coagulant drugs Low platelet count Pregnancy or breast-feeding Previous bronchoscopy within three months of this study

Related Conditions & MeSH terms

• Asthma

Intervention

Other:
• bronchoscopy
bronchoscopy under local anaesthetic and sedation to obtain endobronchial biopsies

Locations

Country	Name	City	State
United Kingdom	Royal Brompton Hospital	London

Sponsors (3)

Lead Sponsor	Collaborator
Imperial College London	Asthma UK, Royal Brompton & Harefield NHS Foundation Trust

Country where clinical trial is conducted

United Kingdom, 

References & Publications (1)

Michaeloudes C, Chang PJ, Petrou M, Chung KF. Transforming growth factor-ß and nuclear factor E2–related factor 2 regulate antioxidant responses in airway smooth muscle cells: role in asthma. Am J Respir Crit Care Med. 2011 Oct 15;184(8):894-903. doi: 10. — View Citation

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	Difference in ASM Mass Between Groups		at time of bronchoscopy, an average of 1 hour
Primary	Difference in ASM Proliferation, Migration and Cytokine Release Between Groups		at time of bronchoscopy, an average of 1 hour
Primary	Difference in Intracellular Oxidative Stress Mechanisms From ASM Between Groups	Expression of Nrf2 protein	at time of bronchoscopy, an average of 1 hour
Secondary	Correlation Between ASM Mass and Airway Hyper-responsiveness (PC20)		at the time of bronchoscopy, an average of 1 hour